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Advanced Colorectal Cancer, Refractory to Infusional Fluorouracil 
Treatment: Efficacy of Second Line Fluorouracil in Combination 
with a Different Biochemical Modulation
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Abstract. Background: Currently there is no standard second may be administered either as bolus or as continuous
line treatment for patients with advanced colorectal cancer infusion. While higher response rates generally have been
(ACC). Previous reports have demonstrated that some patients reported for continuous infusion schedules, this has not yet
may benefit from second line infusional 5-fluorouracil (5-FU) resulted in a survival benefit (1,2). Agents that effectively
after failing 5-FU bolus treatment. Patients and methods: We modulate 5-FU activity are leucovorin (LV) and methotrexate 
retrospectively studied the efficacy and toxicity of infusional 5FU (MTX) (3,4). Other modulators that have been tested in
regimens given in second line, which only differed from the first clinical trials include interferon-a (IFN-a) and N-
line regimen in the type of biochemical modulation and phosphonacetyl-L-aspartic acid (PALA) (5,6). For patients
compared these results in a non-randomized fashion to the resistant to first line treatment with 5-FU no standard
outcome of patients receiving supportive care only in second line, treatment is available. Several small studies have been
Results: Sixty six patients with ACC were treated in first line with published on the use of infusional 5-FU in patients resistant
an infusional 5-FU-based schedule. A t the time of disease to 5-FU bolus therapv (7-10). No data exist on the efficacy of
progression 38 patients received supportive care only. The second line treatment with infusional 5-FU in combination
remaining 28 patients continued treatment with the same 5-FU with a different biochemical modulator and only very few
regimen, but with another biochemical modulator. Fourteen studies have been reported on second line bolus 5-FU in
patients achieved stable disease for a median duration of 6 combination with a different biochemical modulator. The
months and one patient achieved a complete remission which rationale behind these options is that the mechanisms
lasted 34 months. The median survival from the time of disease underlying 5-FU resistance might differ depending on the
progression on first line treatment was 7 months for patients who kind of 5-FU schedule or the type of biochemical modulator
received second line treatment, whereas those who received used. We studied the efficacy and toxicity of infusional 5-FU 
supportive care survived for a median period of 3 months regimens given in second line, which only differed from the
(p<0.05). Conclusion: Changing the type of biochemical modu- first line regimen in the type of biochemical modulation. 
lation of infusional 5-FU as a second line treatment-alternative
may be o f some benefit to a subgroup of patients with ACC. Patients and Methods .
5-Fluorouracil (5-FU) is the most widely used agent in the From 1988 until 1993 66 patients with ACC were entered in 3 different 
treatment of advanced colorectal carcinoma (ACC). During stud‘“  (1„‘-13)- In a11,p“‘ief  “  5‘FU. re«“”e" 60j , . . i mg/kg/48 hours was used. The treatment schedules used in these studies
the last decades research has focussed OH the Optimal are Sh0wn *n j able I. Response was evaluated with an interval of 2 to 3 
administration-schedule of 5-FU and on agents which months. Complete response (CR), partial response (PR), stable disease 
biochemically modulate the cytotoxic effect o f 5-FU. 5-FU (SD) and progressive disease (PD) were defined according to WHO
criteria.
Of these 66 patients 28 patients with PD continued treatment with the 
same schedule of 5-FU, but with a different biochemical modulator than 
the one used in first line treatment. Patients initially treated with 5-FU
Correspondence to: Dr. C J.A . Punt, Department of Medical alone received 5-FU plus LV and patients initially treated with 5-FU 
Oncology, University Hospital, PO Box 9101, 6500 HB plus LV and IFN-a received 5-FU and MTX. Furthermore, patients
Nijmegen, The Netherlands. treated with 5-FU, PALA and MTX received 5-FU and LV and patients 
treated with 5-FU and,MTX received 5-FU and LV. The major selection
Key Words: Colorectal carcinoma, neoplasms, second line criteria for second line chemotherapy were performance status, 
treatment, 5-fluorouracil, biochemical modulation, 5- motivation of the patient for further chemotherapy, as well as adequate
fluorouracil resistance. liver, bone marrow and renal function.
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Table I. Schedules according to which the 66 patients studied had been treated.
Regimen Drug name Number of 
patients
Dose
administered
Mode of ad- 
-ministration
Time of ad- 
-ministration
A11
•
5-FU 16 60 mg/kg continuous iv. 
over 48 hours
day 1,2
B11 5-FU 24 60 mg/kg continuous iv. 
over 48 hours
day 1,2
MTX 40 mg/m2 bolus iv. day 1
c 13 5-FU 4 60 mg/kg continuous iv. 
over 48 hours
day 2,3
MTX 40 mg/m2 bolus iv. day 2
PALA 250 mg/m2 bolus iv. day 1
D12 5-FU 22 60 mg/kg continuous iv. 
over 48 hours
day 1,2
«
LV 90 mg orally every 6 
hours for a 
total of 8 
doses
IFN-a 10 million 
units
s.c. day 1,3 and
5
Treatment was given every week during the first month and every 2 weeks thereafter (c.i.v.=continuous intravenous infusion; i.v.=intravenous; 
s.c.=subcutaneous; numbers correspond with references).
Patients who did and patients who did not receive second line different biochemical modulator. Table II shows the
chemotherapy were compared in terms of overall survival, response rate 
to first line chemotherapy and progression-free survival, as well as 
performance status at the time of discontinuation of first line 
chemotherapy. Furthermore, we analyzed whether second line
responses and survival of these patients. Fourteen patients 
(50%) achieved SD for a median duration of 6 months and 
one patient (4%) achieved a CR which lasted 34 months. The
chemotherapy contributed to a longer survival. For this part of the median progression-free interval was 4 months. Median
analysis survival was measured from the moment of disease progression survival measured from the moment of disease progression 
during first line chemotherapy. The significance of differences between
stochastic variables was estimated by means of the Chi-square test. The
significance of differences between actuarial survival curves was
estimated by means of the Anderson log rank-test.
Results
during first line treatment was significantly better for the 28 
patients who had received second line chemotherapy than for 
the 38 patients who had received supportive care only (7 
months versus 3 months, p<0.05).
Grade I-II toxicities occurred in 17 patients on second line 
chemotherapy (61 %) and grade III gastrointestinal toxicity
For the entire group of 66 patients first line chemotherapy occurred in one patient (4%).
resulted in 34 SD’s (52%) and 8 PR’s (12%). CR’s did not As shown in Tables III and IV, the patients who received
occur. In 24 cases (36%) the disease appeared progressive, second line chemotherapy differed considerably from the
The median progression-free interval was 6 months. patients who received supportive care only. Among former
After disease progression twenty eight patients continued the proportion of patients with SD or a PR to first line 
chemotherapy with the same 5-FU schedule, but with a chemotherapy was higher (p<0.05) and the median
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Table II. Characteristics of the patients who underwent second line treatment,
Patient
No.
Gender Age
(yrs.)
First line therapy Second line therapy
schedule response response
duration
(months)
schedule response response
duration
(months)
Overall
survival
(months)
1 M 4 4Tt 5-FU SD 13 5-FU/LV CR 34 53
2 F 51 5-FU PD * 5-FU/LV PD * 24
3 M 53 5-FU PD * 5-FU/LV PD * 8
4 M 64 5-FU SD 4 5-FU/LV SD 6 12
5 M 45 5-FU SD 9 5-FU/LV SD 4
1
13
6 M 47 5-FU/LV/IFN SD 10 5-FU/MTX PD * 22
7 M 50 5-FU/LV/IFN PR 14 5-FU/MTX SD 19 51
8 M 46 5-FU/LV/IFN SD 16 5-FU/MTX SD 6 30
9 M 54 5-FU/LV/IFN SD 20 5-FU/MTX SD 6 30
10 M 43 5-FU/LV/IFN PR 10 5-FU/MTX PD * 24
11 M 59 5-FU/LV/IFN PR 9 5-FU/MTX SD 5 26
12 M 41 5-FU/LV/IFN PR 18 5-FU/MTX SD 5 25
13 M 66 5-FU/MTX
PALA
PR 15 5-FU/LV SD 6 32
14 M 68 5-FU/MTX
PALA
PD 5-FU/LV PD
«
* 12
15 M 67 5-FU/MTX SD 15 5-FU/LV SD 6 23
16 F 51 5-FU/MTX SD 6 5-FU/LV PD * 15
17 M 59 5-FU/MTX SD 9 5-FU/LV SD 4 13
18 M 46 5-FU/MTX SD 6 5-FU/LV PD * 8
19 M 57 5-FU/MTX SD 6 5-FU/LV SD 13 19
20 M 56 5-FU/MTX SD 9 5-FU/LV SD 5 15
21 M 44 5-FU/MTX PD * 5-FU/LV PD * 7
22 M 29 5-FU/MTX PR 9 5-FU/LV . PD * 15
23 M 52 5-FU/MTX SD 6 5-FU/LV PD * 14
24 M 50 5-FU/MTX SD 19 5-FU/LV SD 5 44
25 M 52 5-FU/MTX SD 9 ' 5-FU/LV PD * 22
26 F 66 5-FU/MTX PD * 5-FU/LV PD * 7
27 F 56 5-FU/MTX PD * 5-FU/LV SD 6 12
28 M 60 5-FU/MTX SD 17 5-FU/LV; k PD * 21
An overview of all patients who received first and second line treatment for advanced colorectal cancer (CR, PR, SD and PD denote complete 
response, partial response, stable disease and progressive disease, respectively; M=male; F=female; 
l=calculated from the start of first line therapy.
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Table III. Survival percentages according to type of treatment.
Duration of Entire Patients who received Patients who did not
’ •
follow up group second line receive second line
(n =66) chemotherapy (n= 28), chemotherapy (n— 3,8)
6 months 76% 100% 64%
12 months 45% 75% 28%
18 months 28% 54% 8%
24 months 16% 29% 5%i
Actuarial overall survival of 66 patients with advanced colorectal cancer 
who received chemotherapy and survival of the subgroups who did (n=  
28) and who did not (n= 38) receive second line chemotherapy.
progression-free interval from -the start of first line 
chemotherapy was longer (8 months vs 3 months, p < 0.01). 
Their median Karnofsky performance status was better at the 
time of discontinuation of first line chemotherapy (90% vs 
70%). Furthermore, their median overall survival from the 
start of first line treatment was significantly longer (20 vs 8 
months, p< 0.001).
Discussion
At present, most patients with ACC are treated in first line 
with a 5-FU-based regimen. In case of progression, there is no 
standard second line regimen available. Several studies 
indicate that in some patients with disease progression on first 
line treatment with bolus 5-FU a response or stabilization of 
disease can be induced by administration of an infusional 
schedule with high-dose 5-FU (7-10). In these studies 
response rates (CR and PR) varied from 5% to 30% with a 
median overall survival of 7.5 months to 10 months.
Our study adresses the question whether patients with 
ACC refractory to treatment with a combination of infusional 
5-FU and one or more biochemical modulators may benefit 
from a second line regimen consisting of the same 5-FU 
schedule, but with a different modulator. Publications 
concerning this question are scarce. Bernhard et al (14) 
studied the value of the addition of IFN-a in 15 patients 
refractory to treatment with 5-FU and LV. Only one minor 
response and one SD were observed; In a study performed by 
Palmieri et al (15) 20 patients with ACC refractory to 
treatment with 5-FU or 5-FU plus LV received a second line 
schedule consisting of 5-FU and MTX. Two PR’s were 
observed and 12 patients achieved SD. The second line 
schedules used in our study (infusional 5FU plus MTX or 
LV) resulted in 50% SD and one CR in 28 patients.
In our study, the baseline characteristics of the patients 
who received second line chemotherapy clearly differed from 
those of patients who received supportive care only. A larger 
proportion had benefitted from first line chemotherapy in 
terms of response and response duration. Furthermore, they
Table IV. Baseline characteristics of the two treatment groups.
< •
• i
i
\
Second line 
chemotherapy 
(n = 28)
No second line 
chemotherapy 
(n=38)
Gender
male n= 23 (82%) n= 28 (74%)
female n= 5 (18%) n= 10 (26%)
Median age 52 years 52 years
Site of métastasés
liver with or without lungs n= 22 (79%) n= 25 (66%)
lungs n= 1 (3%) n= 8 (21%)
locoregional n= 3 (11%) n= 2 (5%)
other n = 2 (7%) n= 3 (8%)
Response to first line
chemotherapy
PD n= 6 (21%) n= 18 (47%)
SD/PD n= 21 (79%) n= 20 (53%)
Percentage of patients free from
progression after first line
chemotherapy
6 months follow up 65% 28%
12 months follow up 33% 8%
18 months follow up 7% 0%
Median Karnofsky performance 90% 70%
status at the time of discontinuation
of first line treatment i
« i
Characteristics of patients with advanced colorectal cancer who did and 
who did not receive second line chemotherapy (PD=progressive 
disease), SD=stable disease, PR=particle remission.
were in better condition at the time of disease progression on 
first line treatment. Second-line treatment was not initiated in 
a prospective randomized fashion and therefore the patients 
that received second line treatment represent a selected 
group of patients. Because the patients receiving second line 
treatment comprised a group with a better prognosis 
compared to the group receiving supportive care only, a direct
comparison between the two groups cannot be made and the
i
difference in overall survival may not be attributed directly to 
the second line treatment. However, our results suggest that 
selected patients refractory to infusional 5-FU may have some 
benefit from second line treatment with infusional 5-FU in 
combination with a different biochemical modulator. 
Alternative possibilities for the treatment of 5-FU resistant 
colorectal cancer are irinotecan (CPT-11) (16) and 5-FU- 
modulation by trimetrexate (17), since these agents have 
shown promising results in phase II studies.
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